Financial Performance - The company's operating revenue for Q3 2024 was ¥153,191,769.07, representing a year-on-year increase of 30.44%[2] - The net profit attributable to shareholders for Q3 2024 was -¥14,339,533.57, a significant decline of 283.31% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was -¥14,622,814.34, reflecting a decrease of 266.8% year-on-year[2] - Total operating revenue for the first three quarters of 2024 was CNY 455,062,228.39, a decrease of 3.4% compared to CNY 470,309,499.48 in the same period of 2023[16] - Net profit for the first three quarters of 2024 was a loss of CNY 12,882,500.66, compared to a net profit of CNY 7,429,981.15 in the same period of 2023[18] - The company reported a total comprehensive loss of CNY 12,882,500.66 for the period, compared to a comprehensive income of CNY 7,429,981.15 in the previous year[19] Assets and Liabilities - The total assets at the end of Q3 2024 were ¥1,248,994,110.76, down 2.22% from the end of the previous year[3] - The equity attributable to shareholders at the end of Q3 2024 was ¥456,619,736.47, a decrease of 2.7% compared to the previous year[3] - The total liabilities decreased to CNY 786,992,360.59 from CNY 803,106,769.70 year-over-year[18] - The company reported a significant reduction in other payables from 20,852,821.16 RMB to 1,181,266.24 RMB, indicating a decrease of approximately 94.3%[14] Cash Flow - The cash flow from operating activities for the year-to-date was ¥6,504,521.27, showing an increase of 105.8% compared to the same period last year[2] - Operating cash inflow for the first nine months reached CNY 510.69 million, an increase from CNY 477.11 million in the previous year, representing an increase of 7%[20] - Net cash flow from operating activities was CNY 6.50 million, a significant improvement from a net outflow of CNY 112.20 million in the same period last year[20] - The company reported a net increase in cash and cash equivalents of CNY 21.93 million, contrasting with a decrease of CNY 34.67 million in the same period last year[21] Shareholder Information - The total number of common shareholders at the end of the reporting period is 10,959[9] - The largest shareholder, Li Ping, holds 118,841,048 shares, representing 41.12% of total shares[11] Expenses - Total operating costs increased to CNY 475,581,980.79, up 1.4% from CNY 469,925,579.12 year-over-year[16] - Research and development expenses rose to CNY 22,845,220.83, an increase of 12.0% from CNY 20,396,280.57 in the previous year[18] - The company reported a significant increase in financial expenses, totaling CNY 6,448,574.48, compared to CNY 2,610,496.79 in the same period last year[18] Accounting Standards - The company has adopted new accounting standards starting in 2024, which may impact future financial reporting[22]

证券代码：603880 证券简称：南卫股份 公告编号：2024-043 江苏南方卫材医药股份有限公司董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 江苏南方卫材医药股份有限公司（以下简称"公司"）控股股东及实际控制人 李平于2024年10月23日收到中国证券监督管理委员会（以下简称"中国证监会"） 下发的《立案告知书》（编号：证监立案字0102024025号），公司财务总监项琴华 于同日收到中国证监会下发的《立案告知书》（编号：证监立案字0102024026号）， 因涉嫌内幕交易，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》 等法律法规，中国证监会决定对李平和项琴华立案。 立案调查期间，公司及相关人员将积极配合中国证监会的调查工作，并严格按 照监管要求履行信息披露义务。目前，公司各项生产经营活动正常有序开展。 公司指定信息披露媒体为《证券时报》、《中国证券报》、《上海证券报》及 上海证券交易所网站（www.sse.com.cn）,有关公司信息以公司在上述指定媒体刊登 的公告为准，敬请广大投资者理性投资 ...

江苏南方卫材医药股份有限公司 简式权益变动报告书 上市公司名称：江苏南方卫材医药股份有限公司 上市地点：上海证券交易所 股票简称：南卫股份 股票代码：603880 信息披露义务人：徐东 住所：辽宁省大连市沙河口区杨树南街 46 号 4-1-2 通讯地址：辽宁省大连市沙河口区杨树南街 46 号 4-1-2 股份变动性质：股份减少，持股比例下降至 5%以下 签署日期：2024 年 10 月 17 日 1 一、信息披露义务人依据《中华人民共和国公司法》、《中华人民共和国证 券法》、《上市公司收购管理办法》、《公开发行证券的公司信息披露内容与格 式准则第 15 号——权益变动报告书》及相关法律、法规、规范性文件编写本权 益变动报告书。 二、信息披露义务人签署本报告已获得必要的授权和批准，其履行亦不违反 信息披露义务人章程及内部规定中的任何条款，或与之相冲突。 三、依据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市 公司收购管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15 号 ——权益变动报告书》的规定，本报告书已全面披露了信息披露义务人在江苏南 方卫材医药股份有限公司中拥有权益的股份变动情况 ...

证券代码：603880 证券简称：南卫股份 公告编号：2024-042 江苏南方卫材医药股份有限公司 关于5%以上股东权益变动的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 本次权益变动属于减持及上市公司限制性股票回购注销，不触及要约收购， 本次权益变动后，徐东先生持有上市公司股份比例从5.355%减少至4.997%，不再是 公司持股5%以上股东。 ● 本次权益变动不会导致公司实际控制人或者第一大股东发生变化。 江苏南方卫材医药股份有限公司（以下简称"公司"）3,432,000 股限制性股 票于 2024 年 7 月 26 日完成注销，公司股本由 292,474,000 股变更至 289,042,000 股，股东徐东先生的持股比例由 5.355%被动增加至 5.419%。 股东徐东先生于 2024 年 9 月 24 日至 2024 年 10 月 16 日，通过上海证券交易所 集中竞价方式累计减持公司股票 1,220,821 股,占公司总股本的 0.422%，徐东先生 持有公司股份比例由 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥301,870,459.32, a decrease of 14.45% compared to ¥352,868,398.82 in the same period last year[13]. - The net profit attributable to shareholders for the first half of 2024 was ¥1,026,478.54, down 87.01% from ¥7,900,369.63 in the previous year[13]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥2,441,224.43, a decrease of 69.98% compared to ¥8,130,725.24 in the same period last year[13]. - Basic earnings per share for the first half of 2024 were ¥0.004, down 86.67% from ¥0.03 in the same period last year[14]. - The weighted average return on net assets for the first half of 2024 was 0.22%, a decrease of 1.05 percentage points from 1.27% in the previous year[14]. - The company reported a net profit margin decline due to increased operating costs, with operating costs at CNY 257,532,656.03 compared to CNY 297,446,083.74 in the previous year[70]. - The total comprehensive income for the first half of 2024 was CNY 1,386,901.49, down from CNY 7,960,072.03 in the first half of 2023[72]. Cash Flow and Assets - The net cash flow from operating activities was ¥3,303,181.38, a significant improvement from a negative cash flow of ¥84,888,400.90 in the previous year[13]. - Cash and cash equivalents increased by 36.98% to ¥131,048,207.62, representing 9.88% of total assets[28]. - Accounts receivable rose by 15.05% to ¥157,580,441.69, accounting for 11.88% of total assets[28]. - Inventory increased by 5.11% to ¥281,754,492.20, making up 21.24% of total assets[28]. - The total assets at the end of the reporting period were ¥1,326,776,241.16, an increase of 3.87% from ¥1,277,326,306.30 at the end of the previous year[13]. - The company's total liabilities reached CNY 850.51 million as of June 30, 2024, compared to CNY 803.11 million at the end of 2023, reflecting an increase of about 5.9%[66]. Research and Development - Research and development expenses amounted to 14,718.90 million yuan, a slight decrease of 0.66% compared to the previous year, focusing on transdermal drug delivery technology and product upgrades[27]. - The company emphasizes technological research and development, collaborating with Zhejiang University to advance transdermal drug delivery technologies, enhancing its competitive edge[22]. - The company holds 11 invention patents, 48 utility models, and 9 design patents, enhancing its competitive edge in technology development[26]. Market Position and Strategy - The company is engaged in the research, production, and sales of transdermal products, medical adhesive tapes, emergency kits, and protective gear[16]. - The company aims to enhance its supply chain and adapt to the evolving market demands driven by an aging population and health consumption upgrades[16]. - The company has established a strong market position as a leading medical device manufacturer in China, leveraging over 30 years of operational experience and the cluster effect of the textile industry in the Yangtze River Delta region[21]. - The company is actively expanding its product categories, particularly in the protective gloves sector, responding to increasing market demands[27]. Compliance and Risk Management - The company did not report any significant risks that could materially affect its operations during the reporting period[2]. - The company has received various certifications, including ISO13485 and FDA approval, ensuring compliance with international quality standards for its medical products[36]. - The company faces risks related to industry policy changes, intensified market competition, and fluctuations in foreign exchange rates, which could adversely affect its operational performance[36]. Shareholder and Corporate Governance - The company’s board approved a shareholder return plan for the next three years (2024-2026), indicating a commitment to returning value to shareholders[37]. - A total of 3.432 million shares of restricted stock will be repurchased and canceled due to unmet performance targets[38]. - The company’s controlling shareholder, Li Ping, committed to not selling shares for six months after the lock-up period and to limit annual transfers to 25% of their total holdings[43]. Environmental and Social Responsibility - The company implemented measures to prevent water pollution, including connecting wastewater to a centralized treatment facility[39]. - The company has developed an emergency response plan for environmental incidents and conducts regular training and drills[41]. - The company operates two gas boilers with an annual natural gas consumption of 1.7 million cubic meters, meeting emission standards[39]. Legal and Regulatory Matters - The company reported a significant lawsuit involving a contract dispute with Beijing Sentai Weiye International Trade Co., Ltd., seeking to terminate the contract and recover funds totaling approximately 973.1 million RMB[49]. - The company has incurred a penalty of 3 million RMB from the China Securities Regulatory Commission for regulatory violations, with key executives also facing fines totaling 4.5 million RMB and 900,000 RMB respectively[51].

江苏南方卫材医药股份有限公司（以下简称"公司"）第四届监事会第十三 次会议于 2024 年 8 月 29 日在公司会议室举行，本次会议采取现场表决的方式召 开。本次会议通知于 2024 年 8 月 19 日以书面、电话和电子邮件方式通知了全体 监事。会议应出席监事 3 人，实际出席监事 3 人。本次会议的通知、召开及审议 程序符合《公司法》、《证券法》等法律法规及《公司章程》的有关规定，所作决 议合法有效。 证券代码：603880 证券简称：南卫股份 公告编号：2024-041 江苏南方卫材医药股份有限公司 第四届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 特此公告。 江苏南方卫材医药股份有限公司 监事会 2024 年 8 月 30 日 二、监事会会议审议情况 1、审议通过《关于公司 2024 年半年度报告全文及摘要的议案》 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）发布的《江 苏南方卫材医药股份有限公司 2024 年半年度报告》及《江 ...

证券代码：603880 证券简称：南卫股份 公告编号：2024-039 江苏南方卫材医药股份有限公司持股 5%以上股东 减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，江苏南方卫材医药股份有限公司（以下简称"南卫 股份"、"公司"）5%以上股东徐东先生持有公司股份 15,662,921 股，占公 司当前总股本的 5.42%。上述股份来源为公司首次公开发行股票并上市前 已有的股份及通过权益分派资本公积转增股本取得的股份及从二级市场集 中竞价交易方式购得的股份，均为无限售条件流通股。 减持计划的主要内容 自本公告披露日起 15 个交易日后的 90 天内，徐东先生拟通过集中竞价方 式减持股份数量不超过 2,890,420 股，即不超过公司股份总数的 1%。自本 公告披露日起 15 个交易日后的 90 天内，徐东先生拟通过大宗交易方式减 持股份数量不超过 5,780,840 股，即不超过公司股份总数的 2%。在减持计 划实施期间发生派发红利、送红股、 ...

关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 江苏南方卫材医药股份有限公司（以下简称"公司"）于 2022 年 4 月 27 日召开第四届董事会第二次会议及第四届监事会第二次会议，审议通过了《关于 调整限制性股票回购数量及回购价格的议案》、《关于回购注销全部激励对象已 获授但尚未解除限售的限制性股票的议案》、《关于变更公司注册资本及修订并 办理变更登记的议案》。公司拟回购注销限制性股票 3,432,000 股，上述注销事 项完成后，公司股本总数将由 292,474,000 股变更为 289,042,000 股。 2024 年 7 月 26 日，公司完成上述已获授但尚未解除限售的限制性股票的回 购注销工作，具体内容详见公司于 2024 年 7 月 24 日披露在上海证券交易所网站 （www.sse.com.cn）的《江苏南方卫材医药股份有限公司股权激励限制性股票回 购注销实施公告》（公告编号：2024-037）。 近日，公司已完成工商变更登记，公司注册资本由人民币 29,247. ...

南京市建邺区贤坤路江岛智立方 C 座 4 层 邮编： 210019 电话： +86 25 - 83304480 传真： +86 25 - 83329335 1 南卫股份限制性股票激励计划 法律意见书 江苏世纪同仁律师事务所 关于江苏南方卫材医药股份有限公司 限制性股票激励计划回购注销部分限制性股票实施情况 之法律意见书 致：江苏南方卫材医药股份有限公司 根据《中华人民共和国公司法》《中华人民共和国证券法》（以下简称"《证 券法》"）《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《律师事 务所从事证券法律业务管理办法》和《律师事务所证券法律业务执业规则（试行）》 等有关法律、法规和规范性文件的规定，本所接受江苏南方卫材医药股份有限公 司（以下简称"南卫股份"或"公司"）委托，就江苏南方卫材医药股份有限公 司限制性股票激励计划（以下简称"本次激励计划"）回购注销部分限制性股票 实施情况（以下简称"本次回购注销实施情况"）出具本法律意见书。 为出具本法律意见书，本所律师特作如下承诺和声明： 南卫股份限制性股票激励计划 法律意见书 江苏世纪同仁律师事务所 关于江苏南方卫材医药股份有限公司 限制性股票激励计 ...

证券代码：603880 证券简称：南卫股份 公告编号：2024-037 江苏南方卫材医药股份有限公司 股权激励限制性股票回购注销实施公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 回购注销原因：江苏南方卫材医药股份有限公司（以下简称"南卫股份"、"公 司"）2021 年当期业绩水平未达到业绩考核目标条件，不满足解除限售条件，公 司将全部激励对象持有的已获授但未解除限售的合计 3,432,000 股限制性股票进行 回购注销。 本次注销股份的有关情况 | 回购股份数量 | 注销股份数量 | 注销日期 | | --- | --- | --- | | 3,432,000股 | 3,432,000股 | 2024年7月26日 | 一、 本次限制性股票回购注销的决策与信息披露 1、2020 年 10 月 20 日，公司召开 2020 年第二次临时股东大会，审议通过了《关 于<南卫股份 2020 年限制性股票激励计划（草案）及其摘要>的议案》（以下简称 "《激励计划》"）、《关于<南卫股份 2020 年限制性股票股 ...